News coverage about CytRx Corporation (NASDAQ:CYTR) has trended somewhat positive on Monday, Accern Sentiment reports. The research firm identifies negative and positive news coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. CytRx Corporation earned a news impact score of 0.13 on Accern’s scale. Accern also gave news articles about the biotechnology company an impact score of 45.9769576294153 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

These are some of the news articles that may have impacted Accern Sentiment’s scoring:

Separately, ValuEngine lowered CytRx Corporation from a “sell” rating to a “strong sell” rating in a research report on Friday, September 1st. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average price target of $2.50.

TRADEMARK VIOLATION WARNING: This news story was first published by Watch List News and is the sole property of of Watch List News. If you are reading this news story on another site, it was copied illegally and reposted in violation of U.S. & international copyright and trademark laws. The correct version of this news story can be read at https://www.watchlistnews.com/somewhat-positive-media-coverage-somewhat-unlikely-to-impact-cytrx-corporation-cytr-share-price/1587693.html.

CytRx Corporation Company Profile

CytRx Corporation is a biopharmaceutical research and development company specializing in oncology. The Company is focused on the clinical development of aldoxorubicin, its modified version of the chemotherapeutic agent, doxorubicin. It is engaged in Phase III trials for aldoxorubicin as a therapy for patients with soft tissue sarcoma (STS) whose tumors have progressed after treatment with chemotherapy.

Insider Buying and Selling by Quarter for CytRx Corporation (NASDAQ:CYTR)

Receive News & Ratings for CytRx Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytRx Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.